成人IgA血管炎(Henoch-Schönlein)的特征与管理:法国多中心回顾性调查260例患者数据
该法国多中心回顾性调查分析了260例成人IgA血管炎(IgAV)患者的临床特征、组织学及治疗反应。基线表现包括紫癜(100%)、关节痛/关节炎/肌痛(61%)、肾小球肾炎(70%)和/或胃肠道受累(53%),30%患者基线有肾功能不全。多变量分析显示糖皮质激素(CS)或CS联合环磷酰胺(CYC)在达到治疗反应上优于秋水仙碱,但CS联合CYC与单用CS的疗效差异因分析方法而异。结论提示单用CS似乎是成人IgAV合理的一线治疗,而加用CYC的获益仍不确定。
要点
- 成人IgAV基线常见紫癜、肾炎和胃肠道受累,30%有肾功能不全。
- 多变量分析中CS或CS联合CYC优于秋水仙碱达到治疗反应。
- CS联合CYC与单用CS的疗效差异因统计模型不同而不一致。
核心结论
- 单用糖皮质激素似乎是成人IgA血管炎合理的一线治疗,而加用环磷酰胺的获益仍不确定。
研究设计与样本
- 法国多中心回顾性调查分析了260例成人IgA血管炎患者的临床特征、组织学特征和治疗反应,并使用不同统计模型比较疗效数据。
主要发现
- 诊断时平均±标准差年龄为50.1±18岁,63%患者为男性。
- 基线表现包括紫癜(100%)、关节痛/关节炎/肌痛(61%)、肾小球肾炎(70%)和/或胃肠道受累(53%)。
- 30%患者基线有肾功能不全。
- 单变量分析中,单用CS治疗者反应率为80%(64/80),CS联合CYC为77%(23/30),秋水仙碱为59%(10/17)(P=0.17)。
- 多变量分析显示CS或CS联合CYC在达到治疗反应上优于秋水仙碱:多变量逻辑回归模型OR 3.68(95%CI 1.10-12.33,P=0.03),倾向评分逆概率加权模型OR 3.75(95%CI 1.28-10.99,P=0.02)。
临床怎么用
- 对于成人IgA血管炎,可考虑单用糖皮质激素作为一线治疗。
- 加用环磷酰胺的获益尚不确定,需结合患者具体情况个体化决策。
局限性
- 原文未明确报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Data on adult IgA vasculitis (Henoch-Schönlein) (IgAV) are scarce. This survey was designed to better define the clinical spectrum of IgAV and efficacy of treatments in a French patient population. METHODS: Data on clinical characteristics, histologic features, and treatment response from 260 patients with IgAV included in a French multicenter retrospective survey were analyzed. Efficacy data were compared using different statistical models. RESULTS: The mean ± SD age of the patients with IgAV at diagnosis was 50.1 ± 18 years, and 63% of patients were male. Baseline manifestations included purpura (100%), arthralgias/arthritis/myalgia (61%), glomerulonephritis (70%), and/or gastrointestinal involvement (53%). Thirty percent of patients showed renal failure at baseline. In univariate analysis, the response to therapy was 80% (64 of 80) in patients treated with corticosteroids (CS) alone, compared to 77% (23 of 30) in patients treated with CS plus cyclophosphamide (CYC) and 59% (10 of 17) in patients treated with colchicine (P = 0.17). Multivariable analysis showed that treatment with CS or CS plus CYC was more effective than colchicine in achieving a response. Efficacy differences were demonstrated using different statistical models: in the multivariable logistic regression model, odds ratio (OR) 3.68, 95% confidence interval (95% CI) 1.10-12.33 (P = 0.03); in the inverse probability weighting on propensity score model, OR 3.75, 95% CI 1.28-10.99 (P = 0.02). The efficacy of CS plus CYC as compared to CS alone was discordant according to the analytic method used. Analysis with the multivariable logistic regression model did not demonstrate a difference between CS plus CYC and CS alone (OR 0.88, 95% CI 0.29-2.67; P = 0.82). In contrast, inverse probability weighting on propensity score showed that CS plus CYC was more effective than CS alone (OR 1.79, 95% CI 1.00-3.20; P = 0.049). CONCLUSION: This series constitutes the largest series of adults with IgAV reported in the literature so far. It provides data on clinical and histologic presentation and therapeutic efficacy, suggesting that CS alone appears to be a reasonable first-line therapy in patients with IgAV, while the benefit of adding CYC to CS remains uncertain.
引用
- Audemard-Verger A, Terrier B, Dechartres A, et al. Characteristics and Management of IgA Vasculitis (Henoch-Schönlein) in Adults: Data From 260 Patients Included in a French Multicenter Retrospective Survey. Arthritis Rheumatol. 2017. PMID: 28605168. doi:10.1002/art.40178
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。